Evidence map›Paper›PMID 33190310›Full record

ReviewAlcoholism, clinical and experimental research2021

A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?

Walter Roberts, Terril L Verplaetse, Vijay A Ramchandani, Sherry A McKee

Abstract readReview
In one paragraph

Review in Alcoholism, clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Associations between trait impulsivity facets and alcohol-impaired driving risk perceptions.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2026
    Article
  3. Article
  4. Human laboratory models of reward in substance use disorder.Pharmacology, biochemistry, and behavior · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Walter RobertsFrom the Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0001-6817-884X
Terril L VerplaetseFrom the Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-2531-6656
Vijay A RamchandaniSection on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
Sherry A McKeeFrom the Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Alcohol Pharmacokinetics and Pharmacodynamics in HumansZIAAA000466 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI RAMCHANDANI, VIJAY ARJUN · 2009 to 2025
$31.2M
Yale-SCORE Resource Support CoreU54AA027989 · NIAAA · YALE UNIVERSITY · PI Kelly P Cosgrove · 2020 to 2026
$13.0M
Sex-Appropriate Treatment Development for Alcohol Use DisordersP01AA027473 · NIAAA · YALE UNIVERSITY · PI PICCIOTTO, MARINA R · 2018 to 2019
$1.0M
Behavioral and Neurochemical Mechanisms Underlying Stress-Precipitated DrinkingK01AA025670 · NIAAA · YALE UNIVERSITY · PI VERPLAETSE, TERRIL L · 2018 to 2023
$882k
Developing a mobile alcohol biosensor platform for use in medication testing researchK23AA026890 · NIAAA · YALE UNIVERSITY · PI ROBERTS, WALTER MCRAINEY · 2019 to 2023
$827k
Alcohol Pharmacokinetics and Pharmacodynamics in HumansZ01AA000466 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI RAMCHANDANI, VIJAY ARJUN · 2006 to 2008
$762k
Does endotoxin administration increase alcohol consumption in individuals with AUD?R03AA028361 · NIAAA · YALE UNIVERSITY · PI VERPLAETSE, TERRIL L · 2021 to 2022
$168k
Intramural NIH HHS Z01 AA000466NCATS NIH HHS UL1 TR001863NIAAA NIH HHS AA025670NIAAA NIH HHS AA026890NIAAA NIH HHS K01 AA025670NIAAA NIH HHS K23 AA026890NIAAA NIH HHS P01 AA027473NIAAA NIH HHS R03 AA028361NIAAA NIH HHS U54 AA027989NIAAA NIH HHS Z1A000466Office of Research on Women's Health AA027989
6 · The paper itself

Abstract

Human laboratory studies play an important role in alcohol use disorder (AUD) medication development. Medications that are found to be safe and effective during human laboratory screening will then move to more expensive clinical trials in patient populations. Given the gatekeeping role of human laboratory studies in the medication development pipeline, it is critical that these studies accurately forecast how pharmacotherapies will perform under true-to-life clinical conditions. On the other hand, the design of these studies also must adhere to ethical guidelines: certain aspects of clinical reality cannot be incorporated into screening studies because doing so might place the participant at risk for harm or breach other ethical guidelines. Conventions exist that guide the resolution of these conflicting ideals. This article considers the practice of recruiting non-treatment-seeking heavy drinkers to participate in laboratory screening studies. By convention, volunteers are excluded from laboratory screening studies that involve alcohol administration if they are deemed "treatment seeking," meaning that they recently stopped drinking or are motivated to do so. Although this common practice may reduce risk to participants, findings may not accurately predict medication effects on treatment seekers. Indeed, there is empirical evidence that treatment seekers differ from nontreatment seekers in their responses to medications (Neuropsychopharmacology 2017a; 42: 1776; Am J Drug Alcohol Abuse 2017b; 43: 703; J Psychiatr Res 2006; 40: 383). Here, we argue for the importance of recruiting treatment seekers for this research due to their qualitative difference from nontreatment seekers. We argue that these individuals should be the default population in human laboratory medication screening studies. We conclude by discussing 2 case examples of medication experiments led by our research groups that involved administering medications to treatment seekers.

Indexed as

Adrenergic alpha-2 Receptor AgonistsAlcohol DeterrentsAlcohol-Related DisordersClinical Trials as TopicGuanfacineHumansNaltrexonePatient SelectionAdrenergic alpha-2 Receptor AgonistsAlcohol DeterrentsGuanfacineNaltrexoneAlcohol AdministrationAlcohol Use DisorderHuman LaboratoryPharmacotherapy DevelopmentResearch Ethics

Identifiers

PMID33190310
PMCPMC7855436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.